Recent Updates
Recently added Catalysts
GILD Positive Sentiment

Gilead Sciences Announces Third Quarter 2026 Financial Results

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gilead Sciences reported strong financial results for Q3 2026, marking the highest year-over-year growth in over a decade. The company raised its full-year revenue guidance, reflecting the robust performance of its business. CEO Daniel O'Day emphasized the strength and durability of Gilead's operations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong year-over-year base business growth reported.
  • Gilead raised its full year revenue guidance.
  • CEO highlighted the strength and durability of the business.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+31%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Zimberelimab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026. “Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this qua

Frequently Asked Questions

What were Gilead's Q3 2026 financial results?

Gilead reported exceptional growth, raising its revenue guidance for the year.

Who is Gilead's CEO?

Daniel O'Day is the Chairman and CEO of Gilead Sciences.

How does Gilead's growth compare to previous years?

This growth is the strongest year-over-year increase in over a decade.

What did Gilead raise in its guidance?

Gilead raised its full-year base business revenue guidance.

ShareAdd on Google
Tags: GILD Gilead Sciences Q3 2026 financial results revenue growth
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$3179M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ZimberelimabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+31%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →